Loading
A phase 1 trial of TLN-121 run by Treeline Biosciences, Inc., now recruiting.
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas is a phase 1 interventional study registered as NCT07082803 by Treeline Biosciences, Inc., with 180 participants planned, started 2025-06-23. Conditions recorded: Lymphoma and Lymphoma, Non Hodgkin. Interventions recorded: TLN-121, zeprumetostat (TLN-254) and TLN-121.
Shares Zeprumetostat, Treeline Biosciences, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Treeline Biosciences and the tag pipeline.
Shares Treeline Biosciences and the tag pipeline.
Shares Zeprumetostat and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/